1. Home
  2. ONCO vs EVAX Comparison

ONCO vs EVAX Comparison

Compare ONCO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.48

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

EVAX

Evaxion Biotech

HOLD

Current Price

$3.83

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONCO
EVAX
Founded
2018
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
31.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ONCO
EVAX
Price
$0.48
$3.83
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
341.3K
31.2K
Earning Date
11-13-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
22.80
N/A
EPS
N/A
N/A
Revenue
$815,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$1.20
52 Week High
$7.65
$12.15

Technical Indicators

Market Signals
Indicator
ONCO
EVAX
Relative Strength Index (RSI) 33.03 54.68
Support Level $0.45 $2.45
Resistance Level $0.95 $6.74
Average True Range (ATR) 0.09 0.36
MACD 0.02 0.08
Stochastic Oscillator 3.33 52.80

Price Performance

Historical Comparison
ONCO
EVAX

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: